Insitro, the AI therapeutics company built on causal biology, today announced the expansion of its strategic collaboration with Bristol Myers Squibb (NYSE: BMY) to advance a broadened portfolio of therapeutic programs for amyotrophic lateral sclerosis (ALS). The collaboration is focused on accelerating and delivering disease-modifying interventions designed to address the underlying biological drivers of ALS.

BMS has nominated two additional targets, ALS-2 and ALS-3, which were identified through insitro's Virtual Human™ platform. These join the initial target, ALS-1, nominated by Bristol Myers Squibb in December 2024. The companies will leverage multiple therapeutic modalities to address the nominated targets. insitro will advance its own oligonucleotide program for ALS-1 while simultaneously progressing a small molecule program for BMS for ALS-1. This multimodality development strategy is designed to maximize the opportunities to impact patients as quickly and effectively as possible. insitro received a $10 million milestone payment in connection with the selection of the two additional targets.